Core Insights - The T1D Fund has appointed Elizabeth Mily as CEO to enhance its leadership and investment strategy, focusing on type 1 diabetes (T1D) solutions [1][2] - Mily brings over 30 years of experience in pharma, healthcare investment banking, and strategic leadership, aiming to expand equity investments and partnerships [1][3] - The T1D Fund is positioned as an impact investor, working with biopharma to develop innovative therapies for T1D [4] Company Overview - The T1D Fund is an impact investment fund established in December 2016, dedicated to accelerating solutions for treating, preventing, and curing type 1 diabetes [5] - It is the first scaled, mission-driven venture impact fund focused on catalyzing the development of T1D cure-oriented therapies through equity investments [5] - The Fund collaborates with leading organizations like Breakthrough T1D and the Helmsley Charitable Trust to align its focus on T1D research [5] Leadership and Strategy - Elizabeth Mily previously served as Executive Vice President at Bristol Myers Squibb, overseeing company strategy and business development [3] - Mily's leadership is expected to enhance the T1D Fund's investment team and strategic partnerships, aiming to create an ecosystem for new therapies [1][4] - The Fund's unique position allows it to proactively engage with biopharma to bring innovative therapies to market [4]
The T1D Fund Appoints Industry Veteran Elizabeth Mily as CEO to Accelerate Development of Type 1 Diabetes Cures Through Impact Investing